Oslo University Hospital Launches Phase 2 Trial of ILB® in ALS for 2026

Oslo University Hospital will initiate a multicentre randomized Phase 2 trial of ILB® in Amyotrophic Lateral Sclerosis (ALS) in early 2026. The study will directly compare ILB® with Riluzole, the current standard of care.

• Patients: 116
• Duration: 12 months
• Design:
  - 6-month double-blind randomized phase (Riluzole vs ILB®)
  - 6-month open-label extension (all patients receive both ILB® and Riluzole)

The trial will be sponsored by Oslo University Hospital, funded through public research grants, and is restricted to Norwegian residents.

Leadership and Oversight

• Coordinating Investigator: Dr. Angelina Hatlø Maniaol, Senior Consultant Neurologist.
• Drug Supply: Tikomed will provide ILB® and matching placebo for the RCT.

The study has received all necessary regulatory approvals and will begin patient enrollment in Q1 2026. Final results are expected by end of 2028.

About ILB® and Tikomed

ILB® is Tikomed’s investigational therapy for neurodegenerative and degenerative disorders. It is a dextran sulphate with a favorable safety profile and encouraging results from small-scale Phase 2a proof-of-concept ALS studies.

Tikomed, based in Viken, Sweden, is privately owned and focused on advancing breakthrough therapies in neurodegeneration.

About ALS

Amyotrophic Lateral Sclerosis (ALS)—also known as Lou Gehrig’s disease—is a severe, progressive, and ultimately fatal neurodegenerative disorder.

• Global prevalence: 250,000–300,000 people.
• New cases annually: ~60,000.
• Prognosis: Average survival is less than 3 years after diagnosis.
• Core symptoms: Declining motor function, progressing to inability to swallow and breathe.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!